Cargando…

Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension

Antiphospholipid syndrome (APS) is a multifactorial, autoantibody-mediated disease. Antiphospholipid antibodies (aPL) directed against negatively charged phospholipids or various combinations of phospholipid-binding proteins seem to be an independent pathogenic factor that plays a critical role in A...

Descripción completa

Detalles Bibliográficos
Autores principales: Romanidou, Gioulia, Konstantinidis, Theocharis G., Koutsogiannis, Odysseas, Grapsa, Anastasia, Kantartzi, Konstantina, Panagoutsos, Stylianos, Panopoulou, Maria, Tsigalou, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313595/
https://www.ncbi.nlm.nih.gov/pubmed/30428599
http://dx.doi.org/10.3390/medsci6040102
_version_ 1783383969101774848
author Romanidou, Gioulia
Konstantinidis, Theocharis G.
Koutsogiannis, Odysseas
Grapsa, Anastasia
Kantartzi, Konstantina
Panagoutsos, Stylianos
Panopoulou, Maria
Tsigalou, Christina
author_facet Romanidou, Gioulia
Konstantinidis, Theocharis G.
Koutsogiannis, Odysseas
Grapsa, Anastasia
Kantartzi, Konstantina
Panagoutsos, Stylianos
Panopoulou, Maria
Tsigalou, Christina
author_sort Romanidou, Gioulia
collection PubMed
description Antiphospholipid syndrome (APS) is a multifactorial, autoantibody-mediated disease. Antiphospholipid antibodies (aPL) directed against negatively charged phospholipids or various combinations of phospholipid-binding proteins seem to be an independent pathogenic factor that plays a critical role in APS. Unfortunately, their role in hypertension is not fully elucidated. The aim of our study was to determine aPL titers in hypertension patients and investigate the association of aPL with renal impairment parameters. Forty-seven patients with arterial hypertension (22 males, 46.8% and 25 females, 53.2%), aged 41–85 years old (mean 65.9 ± 10.1 years), and 21 age-sex-matched subjects without severe hypertension as control group (8 males, 13 females, 38.1% vs. 61.9%), mean age 61 ± 11.3 years, were enrolled in this study. Patients with other risk factors like Rheumatoid Arthritis and Systematic Lupus Erythematosus (SLE), both viral and bacterial acute infections, and cancer were excluded from the study. The aPL (anticardiolipin (ACA) and anti-b2GPI antibodies, IgG and IgM) were measured by ELISA (Aesculisa, Aesku Diagnostics, Wendelsheim, Germany) with a cutoff of 15 GPL/MPL for ACA and 15 U/mL for b2GPI. Serum Neutrophil gelatinase-associated lipocalin (sNGAL) was measured by ELISA kits (BioVendor, Brno, Czech Republic). Biochemical analysis such as serum creatinine (Cr), were measured by automated analyzer and finally estimated glomerular filtration rate (e-GFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Fifteen patients were positive for ACA IgG (31.9%), two for anti-b2GPI IgM (4.2%), and three for anti-b2GPI IgG (6.3%). Furthermore, three persons from control group were positive in anti-b2GPI IgG (14.27%). The serum level of anti-b2GPI IgG was significantly higher in patients compared to healthy controls (p = 0.013). The level of sNGAL (59.63 ± 41.5 ng/mL vs. 45.5 ± 21.5 ng/mL, p = 0.14) was not higher in hypertensive patients than in the age-sex-matched control group. Additionally, the sNGAL level was found to be directly and positively correlated in patients with positive ACA IgG (r(2) = 0,945, p < 0.0001). These results demonstrate that autoimmunity may be one of the pathogenetic factors of hypertension and aPL antibodies might be a potential marker of renal involvement.
format Online
Article
Text
id pubmed-6313595
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63135952019-01-04 Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension Romanidou, Gioulia Konstantinidis, Theocharis G. Koutsogiannis, Odysseas Grapsa, Anastasia Kantartzi, Konstantina Panagoutsos, Stylianos Panopoulou, Maria Tsigalou, Christina Med Sci (Basel) Article Antiphospholipid syndrome (APS) is a multifactorial, autoantibody-mediated disease. Antiphospholipid antibodies (aPL) directed against negatively charged phospholipids or various combinations of phospholipid-binding proteins seem to be an independent pathogenic factor that plays a critical role in APS. Unfortunately, their role in hypertension is not fully elucidated. The aim of our study was to determine aPL titers in hypertension patients and investigate the association of aPL with renal impairment parameters. Forty-seven patients with arterial hypertension (22 males, 46.8% and 25 females, 53.2%), aged 41–85 years old (mean 65.9 ± 10.1 years), and 21 age-sex-matched subjects without severe hypertension as control group (8 males, 13 females, 38.1% vs. 61.9%), mean age 61 ± 11.3 years, were enrolled in this study. Patients with other risk factors like Rheumatoid Arthritis and Systematic Lupus Erythematosus (SLE), both viral and bacterial acute infections, and cancer were excluded from the study. The aPL (anticardiolipin (ACA) and anti-b2GPI antibodies, IgG and IgM) were measured by ELISA (Aesculisa, Aesku Diagnostics, Wendelsheim, Germany) with a cutoff of 15 GPL/MPL for ACA and 15 U/mL for b2GPI. Serum Neutrophil gelatinase-associated lipocalin (sNGAL) was measured by ELISA kits (BioVendor, Brno, Czech Republic). Biochemical analysis such as serum creatinine (Cr), were measured by automated analyzer and finally estimated glomerular filtration rate (e-GFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Fifteen patients were positive for ACA IgG (31.9%), two for anti-b2GPI IgM (4.2%), and three for anti-b2GPI IgG (6.3%). Furthermore, three persons from control group were positive in anti-b2GPI IgG (14.27%). The serum level of anti-b2GPI IgG was significantly higher in patients compared to healthy controls (p = 0.013). The level of sNGAL (59.63 ± 41.5 ng/mL vs. 45.5 ± 21.5 ng/mL, p = 0.14) was not higher in hypertensive patients than in the age-sex-matched control group. Additionally, the sNGAL level was found to be directly and positively correlated in patients with positive ACA IgG (r(2) = 0,945, p < 0.0001). These results demonstrate that autoimmunity may be one of the pathogenetic factors of hypertension and aPL antibodies might be a potential marker of renal involvement. MDPI 2018-11-13 /pmc/articles/PMC6313595/ /pubmed/30428599 http://dx.doi.org/10.3390/medsci6040102 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Romanidou, Gioulia
Konstantinidis, Theocharis G.
Koutsogiannis, Odysseas
Grapsa, Anastasia
Kantartzi, Konstantina
Panagoutsos, Stylianos
Panopoulou, Maria
Tsigalou, Christina
Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title_full Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title_fullStr Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title_full_unstemmed Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title_short Study of Antiphospholipid Antibodies in Patients with Arterial Hypertension
title_sort study of antiphospholipid antibodies in patients with arterial hypertension
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313595/
https://www.ncbi.nlm.nih.gov/pubmed/30428599
http://dx.doi.org/10.3390/medsci6040102
work_keys_str_mv AT romanidougioulia studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT konstantinidistheocharisg studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT koutsogiannisodysseas studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT grapsaanastasia studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT kantartzikonstantina studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT panagoutsosstylianos studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT panopouloumaria studyofantiphospholipidantibodiesinpatientswitharterialhypertension
AT tsigalouchristina studyofantiphospholipidantibodiesinpatientswitharterialhypertension